These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute myocardial infarction. Gibson CM; Korjian S; Tricoci P; Daaboul Y; Alexander JH; Steg PG; Lincoff AM; Kastelein JJ; Mehran R; D'Andrea D; Merkely B; Zarebinski M; Ophius TO; Harrington RA Am Heart J; 2016 Oct; 180():22-8. PubMed ID: 27659879 [TBL] [Abstract][Full Text] [Related]
11. CSL112 Infusion Rapidly Increases APOA1 Exchange Rate via Specific Serum Amyloid-Poor HDL Subpopulations When Administered to Patients Post-Myocardial Infarction. Didichenko SA; Velkoska E; Navdaev AV; Greene BH; Lorkowski SW; Duffy D; Mears SJ; Wright SD; Gibson CM; Smith JD; Kingwell BA Arterioscler Thromb Vasc Biol; 2023 Jun; 43(6):855-869. PubMed ID: 36994730 [TBL] [Abstract][Full Text] [Related]
12. The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction. Gibson CM; Kerneis M; Yee MK; Daaboul Y; Korjian S; Mehr AP; Tricoci P; Alexander JH; Kastelein JJP; Mehran R; Bode C; Lewis BS; Mehta R; Duffy D; Feaster J; Halabi M; Angiolillo DJ; Duerschmied D; Ophuis TO; Merkely B Am Heart J; 2019 Feb; 208():81-90. PubMed ID: 30580130 [TBL] [Abstract][Full Text] [Related]
13. Pharmacometric analyses to characterize the effect of CSL112 on apolipoprotein A-I and cholesterol efflux capacity in acute myocardial infarction patients. Zheng B; Duffy D; Tricoci P; Kastrissios H; Pfister M; Wright SD; Gille A; Tortorici MA Br J Clin Pharmacol; 2021 Jun; 87(6):2558-2571. PubMed ID: 33217027 [TBL] [Abstract][Full Text] [Related]
14. CSL112 enhances biomarkers of reverse cholesterol transport after single and multiple infusions in healthy subjects. Gille A; Easton R; D'Andrea D; Wright SD; Shear CL Arterioscler Thromb Vasc Biol; 2014 Sep; 34(9):2106-14. PubMed ID: 24969776 [TBL] [Abstract][Full Text] [Related]
15. Moderate Renal Impairment Does Not Impact the Ability of CSL112 (Apolipoprotein A-I [Human]) to Enhance Cholesterol Efflux Capacity. Gille A; Duffy D; Tortorici MA; Wright SD; Deckelbaum LI; D'Andrea DM J Clin Pharmacol; 2019 Mar; 59(3):427-436. PubMed ID: 30452776 [TBL] [Abstract][Full Text] [Related]
16. Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial. Tricoci P; D'Andrea DM; Gurbel PA; Yao Z; Cuchel M; Winston B; Schott R; Weiss R; Blazing MA; Cannon L; Bailey A; Angiolillo DJ; Gille A; Shear CL; Wright SD; Alexander JH J Am Heart Assoc; 2015 Aug; 4(8):e002171. PubMed ID: 26307570 [TBL] [Abstract][Full Text] [Related]
17. Effect of CSL112 (apolipoprotein A-I [human]) on cholesterol efflux capacity in Japanese subjects: Findings from a phase I study and a cross-study comparison. Zheng B; Goto S; Clementi R; Feaster J; Duffy D; Dalitz P; Airey J; Korjian S; Tortorici MA; Roberts J; Gibson CM Clin Transl Sci; 2022 Oct; 15(10):2331-2341. PubMed ID: 35933730 [TBL] [Abstract][Full Text] [Related]
18. A multiple ascending dose study of CSL112, an infused formulation of ApoA-I. Easton R; Gille A; D'Andrea D; Davis R; Wright SD; Shear C J Clin Pharmacol; 2014 Mar; 54(3):301-10. PubMed ID: 24122814 [TBL] [Abstract][Full Text] [Related]
19. Enhanced HDL Functionality in Small HDL Species Produced Upon Remodeling of HDL by Reconstituted HDL, CSL112: Effects on Cholesterol Efflux, Anti-Inflammatory and Antioxidative Activity. Didichenko SA; Navdaev AV; Cukier AM; Gille A; Schuetz P; Spycher MO; Thérond P; Chapman MJ; Kontush A; Wright SD Circ Res; 2016 Sep; 119(6):751-63. PubMed ID: 27436846 [TBL] [Abstract][Full Text] [Related]
20. [Associations between various lipid components and premature myocardial infarction: a cross-sectional study]. Shi J; Zhang HY; Wang DY; Gao Q; Sheng L; Song PW; Zhang Y; Li Y Zhonghua Xin Xue Guan Bing Za Zhi; 2023 Mar; 51(3):278-287. PubMed ID: 36925138 [No Abstract] [Full Text] [Related] [Next] [New Search]